Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ERBB4 |
| Variant | K751M |
| Impact List | missense |
| Protein Effect | loss of function |
| Gene Variant Descriptions | ERBB4 K751M lies within the protein kinase domain of the Erbb4 protein (UniProt.org). K751M results in a loss of Erbb4 protein function as demonstrated by a loss of kinase activity in cell culture (PMID: 19718025, PMID: 21110957). |
| Associated Drug Resistance | |
| Category Variants Paths |
ERBB4 mutant ERBB4 inact mut ERBB4 K751M |
| Transcript | NM_005235.3 |
| gDNA | chr2:g.211619226T>A |
| cDNA | c.2252A>T |
| Protein | p.K751M |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_005235 | chr2:g.211619226T>A | c.2252A>T | p.K751M | RefSeq | GRCh38/hg38 |
| NM_001042599.1 | chr2:g.211619226T>A | c.2252A>T | p.K751M | RefSeq | GRCh38/hg38 |
| NM_001042599.1 | chr2:g.211619226T>A | c.2252A>T | p.K751M | RefSeq | GRCh38/hg38 |
| NM_005235.2 | chr2:g.211619226T>A | c.2252A>T | p.K751M | RefSeq | GRCh38/hg38 |
| NM_005235.3 | chr2:g.211619226T>A | c.2252A>T | p.K751M | RefSeq | GRCh38/hg38 |
| NM_001042599 | chr2:g.211619226T>A | c.2252A>T | p.K751M | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB4 mutant | lung squamous cell carcinoma | predicted - sensitive | Afatinib | Phase III | Actionable | In a Phase III trial (LUX-Lung 8), secondary analysis demonstrated favorable outcomes with Gilotrif (afatinib) treatment compared to Tarceva (erlotinib) in lung squamous cell carcinoma patients with ERBB (HER) family mutations, and ERBB4 (HER4) mutations predicted an OS (HR=0.22) and PFS (HR=0.21) benefit for Gilotrif (afatinib) over Tarceva (erlotinib) treatment (PMID: 29902295; NCT01523587). | 29902295 |